BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 16275899)

  • 1. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent.
    Greig NH; Utsuki T; Ingram DK; Wang Y; Pepeu G; Scali C; Yu QS; Mamczarz J; Holloway HW; Giordano T; Chen D; Furukawa K; Sambamurti K; Brossi A; Lahiri DK
    Proc Natl Acad Sci U S A; 2005 Nov; 102(47):17213-8. PubMed ID: 16275899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine.
    Darvesh S; McDonald RS; Darvesh KV; Mataija D; Conrad S; Gomez G; Walsh R; Martin E
    Bioorg Med Chem; 2007 Oct; 15(19):6367-78. PubMed ID: 17681768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Butyrylcholinesterase-knockout reduces brain deposition of fibrillar β-amyloid in an Alzheimer mouse model.
    Reid GA; Darvesh S
    Neuroscience; 2015 Jul; 298():424-35. PubMed ID: 25931333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1,4-Substituted 4-(1H)-pyridylene-hydrazone-type inhibitors of AChE, BuChE, and amyloid-β aggregation crossing the blood-brain barrier.
    Prinz M; Parlar S; Bayraktar G; Alptüzün V; Erciyas E; Fallarero A; Karlsson D; Vuorela P; Burek M; Förster C; Turunc E; Armagan G; Yalcin A; Schiller C; Leuner K; Krug M; Sotriffer CA; Holzgrabe U
    Eur J Pharm Sci; 2013 Jul; 49(4):603-13. PubMed ID: 23643737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Butyrylcholinesterase as a Diagnostic and Therapeutic Target for Alzheimer's Disease.
    Darvesh S
    Curr Alzheimer Res; 2016; 13(10):1173-7. PubMed ID: 27040140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective acetyl- and butyrylcholinesterase inhibitors reduce amyloid-β ex vivo activation of peripheral chemo-cytokines from Alzheimer's disease subjects: exploring the cholinergic anti-inflammatory pathway.
    Reale M; Di Nicola M; Velluto L; D'Angelo C; Costantini E; Lahiri DK; Kamal MA; Yu QS; Greig NH
    Curr Alzheimer Res; 2014; 11(6):608-22. PubMed ID: 24359497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating 1,2,3,4,5,6-hexahydroazepino[4,3-b]indole as scaffold of butyrylcholinesterase-selective inhibitors with additional neuroprotective activities for Alzheimer's disease.
    Purgatorio R; de Candia M; Catto M; Carrieri A; Pisani L; De Palma A; Toma M; Ivanova OA; Voskressensky LG; Altomare CD
    Eur J Med Chem; 2019 Sep; 177():414-424. PubMed ID: 31158754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer's agents.
    Košak U; Knez D; Coquelle N; Brus B; Pišlar A; Nachon F; Brazzolotto X; Kos J; Colletier JP; Gobec S
    Bioorg Med Chem; 2017 Jan; 25(2):633-645. PubMed ID: 27908752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
    Duysen EG; Li B; Darvesh S; Lockridge O
    Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease.
    Liston DR; Nielsen JA; Villalobos A; Chapin D; Jones SB; Hubbard ST; Shalaby IA; Ramirez A; Nason D; White WF
    Eur J Pharmacol; 2004 Feb; 486(1):9-17. PubMed ID: 14751402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The exploration of thienothiazines as selective butyrylcholinesterase inhibitors.
    Karlsson D; Fallarero A; Brunhofer G; Mayer C; Prakash O; Mohan CG; Vuorela P; Erker T
    Eur J Pharm Sci; 2012 Aug; 47(1):190-205. PubMed ID: 22683890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
    Pacheco G; Palacios-Esquivel R; Moss DE
    J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Echinacoside ameliorates the memory impairment and cholinergic deficit induced by amyloid beta peptides via the inhibition of amyloid deposition and toxicology.
    Shiao YJ; Su MH; Lin HC; Wu CR
    Food Funct; 2017 Jun; 8(6):2283-2294. PubMed ID: 28581010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease.
    Martinez A; Castro A
    Expert Opin Investig Drugs; 2006 Jan; 15(1):1-12. PubMed ID: 16370929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an in-vivo active reversible butyrylcholinesterase inhibitor.
    Košak U; Brus B; Knez D; Šink R; Žakelj S; Trontelj J; Pišlar A; Šlenc J; Gobec M; Živin M; Tratnjek L; Perše M; Sałat K; Podkowa A; Filipek B; Nachon F; Brazzolotto X; Więckowska A; Malawska B; Stojan J; Raščan IM; Kos J; Coquelle N; Colletier JP; Gobec S
    Sci Rep; 2016 Dec; 6():39495. PubMed ID: 28000737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tacrine-flurbiprofen hybrids as multifunctional drug candidates for the treatment of Alzheimer's disease.
    Chen Y; Sun J; Peng S; Liao H; Zhang Y; Lehmann J
    Arch Pharm (Weinheim); 2013 Dec; 346(12):865-71. PubMed ID: 24203864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-amyloid-related peptides inhibit potassium-evoked acetylcholine release from rat hippocampal slices.
    Kar S; Seto D; Gaudreau P; Quirion R
    J Neurosci; 1996 Feb; 16(3):1034-40. PubMed ID: 8558231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain.
    Mesulam M; Guillozet A; Shaw P; Quinn B
    Neurobiol Dis; 2002 Feb; 9(1):88-93. PubMed ID: 11848688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-beta peptide.
    Utsuki T; Yu QS; Davidson D; Chen D; Holloway HW; Brossi A; Sambamurti K; Lahiri DK; Greig NH; Giordano T
    J Pharmacol Exp Ther; 2006 Aug; 318(2):855-62. PubMed ID: 16690718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease.
    Lahiri DK; Farlow MR; Hintz N; Utsuki T; Greig NH
    Acta Neurol Scand Suppl; 2000; 176():60-7. PubMed ID: 11273593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.